Recombinant bacillus Calmette-Guérin as a potential vector for preventive HIV type 1 vaccines

In August 1997, the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) convened an expert working group to discuss current strategies for the development of HIV type 1 vaccines. Based on the recent findings of investigators from Japan's National Institute of Infectious Diseases (NIID) in Tokyo using recombinant bacillus Calmette-Guérin (rBCG) as a potential vectored vaccine for HIV, a recommendation was made that further work in this area is a priority. As a result, the working group reconvened in September 1998 to discuss the progress to date with this vaccine approach, as well as areas of related research to assess the feasibility of a BCG-vectored HIV vaccine. This report summarizes the discussions addressing the available scientific data on the potential use of rBCG as a vector for preventive HIV vaccines, the work necessary to move such candidate vaccines into Phase 1 clinical trials, and recommendations targeted at facilitating the long-term development of rBCG-vectored HIV vaccines.


Published in:
AIDS research and human retroviruses, 16, 2, 91-8
Year:
2000
Publisher:
Mary Ann Liebert
ISSN:
0889-2229
Keywords:
Laboratories:




 Record created 2010-10-19, last modified 2018-03-17


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)